Procoagulant activity of reversibly acylated human factor Xa.
The plasma clotting factors used to treat hemophiliacs who have developed inhibitory antibodies have a shared history of limited clinical safety and utility. To improve on existing bypass factors, we have developed a reversibly acylated form of human plasma factor Xa capable of providing a time-dependent release of procoagulant activity. Factor Xa was treated with p-amidinophenyl p'-anisate to generate anisoyl Xa. The chemical modification of the protein involves acylation of the active site serine residue of factor Xa. Anisoyl Xa deacylated in a time, pH, and temperature-dependent manner. Active factor Xa generated on deacylation of anisoyl Xa exhibited amidolytic and prothrombinase complex activities in in vitro assays, the level being comparable to those of untreated factor Xa. When Anisoyl Xa was infused into rabbits, active factor Xa was generated on deacylation of the acylated enzyme, which shortened the activated partial thromboplastin time (APTT) in a dose-dependent manner. The duration of effect on rabbit APTT could be directly correlated to the level of human plasma factor Xa. Because anisoyl Xa bypasses the "tenase" complex that is compromised in hemophilia A and B and is unaffected by inhibitory antibodies, it has the potential to be used as an effective bypass therapy.
D000215:Acylation; D000818:Animals; D001665:Binding Sites; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology*; D015943:Factor Va / Q000378:metabolism; D015951:Factor Xa / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy; D002836:Hemophilia B / Q000097:blood / Q000188:drug therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D010314:Partial Thromboplastin Time; D011817:Rabbits; D012694:Serine / Q000737:chemistry
D012694:Serine; D015943:Factor Va; D015951:Factor Xa